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ABSTRACT
Background Most patients with mental illness are 
managed in primary care, yet there is a lack of data 
exploring potential prescribing safety issues in this setting 
for this population.
Objectives Examine the prevalence of, between- 
practice variation in, and patient and practice- level 
risk factors for, 18 mental health- related potentially 
hazardous prescribing indicators and four inadequate 
medication monitoring indicators in UK primary care.
Method Cross- sectional analyses of routinely collected 
electronic health records from 361 practices contributing 
to Clinical Practice Research Datalink GOLD database. 
The proportion of patients ’at risk’ (based on an existing 
diagnosis, medication, age and/or sex) triggering each 
indicator and composite indicator was calculated. 
To examine between- practice variation, intraclass 
correlation coefficient (ICC) and median OR (MOR) were 
estimated using two- level logistic regression models. The 
relationship between patient and practice characteristics 
and risk of triggering composites including 16 of the 18 
prescribing indicators and four monitoring indicators 
were assessed using multilevel logistic regression.
Results 9.4% of patients ’at risk’ (151 469 of 1 
611 129) triggered at least one potentially hazardous 
prescribing indicator; between practices this ranged 
from 3.2% to 24.1% (ICC 0.03, MOR 1.22). For 
inadequate monitoring, 90.2% of patients ’at risk’ 
(38 671 of 42 879) triggered at least one indicator; 
between practices this ranged from 33.3% to 100% 
(ICC 0.26, MOR 2.86). Patients aged 35–44, females 
and those receiving more than 10 repeat prescriptions 
were at greatest risk of triggering a prescribing 
indicator. Patients aged less than 25, females and those 
with one or no repeat prescription were at greatest risk 
of triggering a monitoring indicator.
Conclusion Potentially hazardous prescribing and 
inadequate medication monitoring commonly affect 
patients with mental illness in primary care, with marked 
between- practice variation for some indicators. These 
findings support health providers to identify improvement 
targets and inform development of improvement efforts 
to reduce medication- related harm.
INTRODUCTION
Medications are the most commonly used 
treatment for mental illness,1 and there 
has been substantial growth in the propor-
tion of individuals worldwide using medi-
cations for mental illness.2–5 Prescribing 
medications for patients with mental 
illness may be complicated by high- dose 
antipsychotics and combination regimens, 
the use of psychotropics with high risk of 
harm, high prevalence of patient comor-
bidities and polypharmacy creating drug–
disease and drug–drug interactions which 
may increase the risk of harmful adverse 
events.6 A recent systematic review and 
meta- analysis reported that the highest 
prevalence of preventable harm due to 
medication was at the prescribing and 
monitoring stages of the medication use 
process, and psychotropic medication 
was among the most common therapeutic 
groups associated with preventable medi-
cation harm.7
However, most medication safety 
research for patients with mental illness 
has focused on hospital settings, with 
little data available on prescribing 
safety in primary care for this popu-
lation.8 9 This is important as primary 
care is often the first point of contact for 
people with mental illness with ~90% of 
adults managed entirely in primary care, 
including those with high levels of need 
and complexity.10–12 There is evidence 
that patients with mental illness may 
experience poor quality care affecting 
both their physical and mental healthcare 
needs in primary care.10 12 Also, research 
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practitioner (GP) trainees in England and Wales under-
took a training placement in a mental health setting 
between 2013 and 2015.13 Accordingly, GPs may 
not always feel capable of managing patients with 
mental illness and making alterations to an established 
treatment.10 In addition, the increasing demand for 
primary care services globally, which is expected to 
grow, may further impact adversely on the quality of 
care provided for patients with mental illness.12 14–17
Prescribing safety indicators (PSIs) provide a means 
of assessing prescribing safety, identifying patients at 
high risk of medicine- related harm, enabling inter-
ventions and helping to avoid patient harm and its 
consequences such as hospitalisation.18 19 Use of PSIs 
has been growing in keeping with the WHO’s Third 
Global Patient Safety Challenge in 2017 ‘Medication 
Without Harm’, which recognises the importance of 
hazardous prescribing.20 21 Suites of PSIs are already 
forming part of several successful multifaceted inter-
ventions in the UK and the USA, allowing for real- 
time feedback on prescribing safety in primary care to 
reduce the risk of preventable drug- related harm.21–29 
Across England, PSIs have been rolled out to electron-
ically search clinical records and identify individual 
patients at risk of hazardous prescribing in primary 
care.30 They are also being used for benchmarking at 
practice level as with the National Therapeutic Indi-
cators in Scotland, the National Prescribing Indicators 
in Wales and the Quality and Outcomes Framework 
(QOF) in England.31–33 However, in all these initia-
tives, a limited number of mental health- related PSIs 
were included. To address this need, the first mental 
health- related suite of PSIs has been recently devel-
oped using the Delphi method following a systematic 
review to identify a comprehensive list of potential 
PSIs from published literature.34 35 This suite covers a 
broad range of contemporary safety concerns under a 
range of different mental health problems and related 
medication classes, but has yet to be implemented in 
primary care health records, and the prevalence of 
potentially hazardous prescribing in those with mental 
illness therefore remains unknown. Therefore, the aim 
of this research study was to evaluate prescribing safety 
for patients with mental illness in UK primary care 
using a tailored PSI suite by examining their preva-
lence, variation between general practices, and patient 
and practice- level risk factors, while also determining 
their practice- level reliability.
METHODS
Study design, data source and population
A cross- sectional study was carried out using data 
retrieved from the Clinical Practice Research Data-
link (CPRD GOLD), a primary care database of 
anonymised electronic health records from contrib-
uting general practices in the UK.36 It includes approx-
imately 6.9% of the UK population, and is considered 
broadly representative of the general population in 
terms of age, sex and ethnicity.36
The study population consisted of all patients regis-
tered with general practices in the UK contributing to 
the CPRD GOLD, who had uploaded data after the 
audit date (30 September 2019) and were deemed 
to be of research quality 12 months before the audit 
date (ie, before 1 October 2018). Research quality was 
determined using the two sets of data quality criteria 
provided by the CPRD: acceptability for patients 
(ie, registration status, recording of events and valid 
age and gender) and up to standard time for prac-
tices (ie, continuity of recording).36 Within the study 
population, data were extracted for all patients with 
the potential to trigger each PSI based on an existing 
diagnosis, medication, their age and/or sex. Diagnoses 
and prescriptions of medications are recorded in the 
CPRD using Read codes and product codes, respec-
tively. The codes to define each PSI were reviewed by 
two pharmacists of the research team (RNK and DS). 
A full list of the codes is available at the ClinicalCodes 
repository (https:// clinicalcodes. rss. mhs. man. ac. uk).37 
A drug preparation algorithm published previously 
was used to prepare drug exposure data.38 39
Outcomes
We operationalised a subset of 22 PSIs (18 potentially 
hazardous prescribing indicators and four inadequate 
medication monitoring indicators) from a recently 
developed mental health- related PSI suite that are 
relevant to primary care and feasible for application 
in the CPRD GOLD data.35 Relevance and feasibility 
were established by the research team which included 
a specialist mental health pharmacist (RNK) and a 
pharmacoepidemiologist (DS) with experience in 
using CPRD data. Indicators were not included if the 
data were not captured in the CPRD such as over- the- 
counter therapy, or if the indicator contained a medi-
cation usually prescribed by mental health trusts that 
might not be recorded in GP records such as clozapine 
and long- acting antipsychotic injections.36 40 Online 
supplemental file 1 lists the 22 included PSIs with their 
operational definitions.
To examine their prevalence, each PSI comprised 
a denominator and a numerator. The denominator 
included all patients with the potential to trigger an 
indicator based on an existing diagnosis, medication, 
their age and/or sex. For example, with indicator P10, 
patients would be included in the denominator if they 
had a record of dementia diagnosis, and for indicator 
P11, patients would be included if they were aged 65 or 
older, more than 6 months before the audit date. The 
numerator included patients who triggered the indi-
cator by receiving the potentially hazardous prescrip-
tion, having no record of the required monitoring or 
having no record of the recommended prescription.
Additionally, three composite indicators were 
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assess the risk factors.41–44 For each composite indi-
cator, patients were eligible to be included if they 
were ‘at risk’ for any one of the relevant individual 
indicators, and if a patient was eligible for more than 
one indicator they were counted once. Therefore, the 
composite indicators describe the number of patients 
triggering at least one of the relevant indicators divided 
by the number of patients with the potential to trigger 
any of the relevant indicators. The first composite 
consisted of all potentially hazardous prescribing indi-
cators (P1–P18), the second consisted of all inadequate 
medication monitoring indicators (M1–M4) and the 
third consisted of all potentially hazardous prescribing 
indicators except P11 (specifically for the elderly) and 
P13 (specifically for female patients). The reason for 
excluding these two indicators was to allow relevant 
comparisons between genders and age groups in terms 
of the overall risk.
Statistical analysis
The proportion of patients triggering each PSI and 
composite indicator was calculated with 95% CIs. 
To examine the variability in the prevalence of PSIs 
between practices, the intraclass correlation coefficient 
(ICC) was estimated using an empty two- level logistic 
regression model and a two- level logistic regression 
model adjusted with patient variables, age (5- knot 
restricted cubic spline), sex and number of repeat 
medications. The ICC estimates the proportion of the 
total variation in an indicator that is attributable to the 
variation between practices.42 In addition, we calcu-
lated the median OR (MOR) for each indicator using 
the same case- mix model. The MOR is the median 
of all possible ORs of triggering an indicator in two 
patients with identical characteristics, but registered 
with two different practices. It can also be conceptu-
alised as the increased risk that an individual would 
encounter when moving from one practice to another. 
The MOR is always equal to or higher than 1. Higher 
MOR values indicate more variation between prac-
tices. The advantage of the MOR is that it is directly 
comparable with the ORs for patient and practice- 
level variables.45 46
Furthermore, the reliability for each PSI and 
each composite indicator was estimated using the 













 , where n represents the 
number of patients in the denominator per practice.42 
The reliability coefficient indicates if the observed 
practice- level variation is due to true practice differ-
ences or due to chance.47 For example, an indicator 
with a low ICC value would require higher numbers of 
‘patients at risk’ for a reliable comparison.42 The reli-
ability ranges between 0 and 1, where a higher value 
indicates a higher level of reliability. Values greater than 
0.7 are usually deemed to suggest adequate reliability 
for benchmarking.41 The reliability for a theoretical 
practice (using the median number of patients in the 
denominator) was calculated to provide an overall 
estimate of reliability. The proportion of practices with 
a reliability measure greater than 0.7 was measured. To 
visualise the variation between practices, funnel plots 
of the observed proportions and caterpillar plots of the 
shrunken practice- level residuals (with 95% CIs) from 
the case- mix model were generated for each PSI and 
each composite indicator with an overall reliability 
greater than 0.7 (online supplemental file 2).
The associations between potentially hazardous 
prescribing (composite 3) and inadequate medication 
monitoring (composite 2) with both practice- level and 
patient- level variables were examined using two- level 
logistic regressions. Initially, unadjusted ORs with 95% 
CIs were calculated and then subsequently adjusted 
for patient and practice variables. Patient- level vari-
ables considered were age group (<25, 25–34, 35–44, 
45–54, 55–64, 65–74 and >74), sex and number of 
repeat medications (0–1, 2–4, 5–7, 8–10 and >10), 
which is defined as ≥3 prescriptions of the same medi-
cine within the 12 months leading up to 30 September 
2019.48 Practice- level variables were number of 
patients per general practice (<6000, 6001–9000, 
9001–12 000 and >12 000), practice- level index of 
multiple deprivation (IMD) quintile and location of 
practice by country of the UK. The covariates were 
selected based on prior literature.41 42 Composite 1 
was not included in this analysis as P11 was not rele-
vant to all age groups and P13 was not relevant to both 
genders. Statistical analyses were performed using Stata 
V.16 (StataCorp, College Station, Texas). Funnel plots 
were created using a tool by Public Health England.49
RESULTS
A total of 361 general practices were eligible for inclu-
sion with 3 001 877 registered patients. Most included 
practices were from Scotland (n=159, 43%), followed 
by England (n=99, 26.8%), Wales (n=98, 26.5%) and 
Northern Ireland (n=14, 3.8%). In total, 1 613 207 
(53.8%) patients were at risk of triggering any one 
of the 22 PSIs due to their age, sex, disease and/or 
prescription. Table 1 shows the observed prevalence, 
ICCs, MOR and reliability of each PSI and composite 
indicator. The online supplemental file 2 shows the 
variation between practices for each indicator and 
each composite indicator with adequate reliability 
before and after adjusting for patient characteristics.
Prevalence of composite indicators
For the composite that contained only prescribing- 
related indicators (composite 1, P1–P18), 151 469 
of 1 611 129 (9.4%, 95% CI 9.4% to 9.5%) at- risk 
patients were affected by at least one potentially 
hazardous prescription. For the composite that 
included only monitoring indicators (composite 2, 
M1–M4), 38 671 of 42 879 (90.2%, 95% CI 89.9% 
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potentially hazardous medication- monitoring episode. 
For composite 3 (P1–P18 excluding P11 and P13), 136 
664 of 882 653 (15.5%, 95% CI 15.4% to 15.6%) 
patients received at least one potentially hazardous 
prescription.
Prevalence of individual PSIs
The proportion of patients triggering each indicator 
varied considerably across the 22 PSIs from 0.2% to 
92.6%. For the potentially hazardous prescribing indi-
cators, the prevalence ranged from 0.2% to 90.6%. 
For the inadequate monitoring indicators, the prev-
alence ranged from 24.3% to 92.6%. Of those that 
triggered at least one indicator, the majority triggered 
just one indicator (n=110 144, 65.7%), 20.9% (n=35 
093) triggered two indicators, 8% (n=13 439) trig-
gered three indicators and 5.4% (n=9108) triggered 
at least four indicators.
Variation between practices
Variation between practices in terms of the observed 
prevalence of potentially hazardous prescribing meas-
ured by prescribing composite (P1–P18, composite 
1) ranged from 3.2% to 24.1% (median 9.3%, IQR 
7.6%–11.2%). However, when measured using the 
ICC, 3% of this variation was attributable to differ-
ences between practices, and only 1% persisted after 
adjusting for patient characteristics. The MOR value 
was 1.22 (95% CI 1.20 to 1.24). For the monitoring 
composite (M1–M4, composite 2), the observed prev-
alence ranged from 33.33% to 100% (median 91.8%, 
IQR 84.54%–96.9%), with 27% of variation being 
due to differences between practices after adjusting for 
patient characteristics and MOR 2.86 (95% CI 2.60 
to 3.18). Figure 1 shows the proportion of patients 
receiving potentially hazardous prescribing and inad-
equate medication monitoring for each general prac-
tice.
Of the 22 PSIs, eight prescribing indicators and three 
monitoring indicators had reliability scores lower than 
the recommended level of 0.7 for a practice that was 
of median size of all practices implying inadequate 
reliability. The proportion of practices with adequate 
reliability for the remaining indicators ranged from 
66.2% to 100%. However, all composite indicators 
had reliability scores above 0.9, with over 99% of 
practices having reliability >0.7.
When investigating the variation of individual PSIs, 
after controlling for patient characteristics, the highest 
variation for a prescribing PSI was for P16 (related 
to prescribing two medications with anticholinergic 
activity) with ICC=0.12 and MOR=1.92 (95% CI 
1.69 to 2.24). However, the highest variation for 
prescribing PSIs with adequate reliability (>0.7) was 
for P10 and P11 (both related to benzodiazepine or 
Z- drug prescribing) with ICC=0.5 for both PSIs and 
MOR=1.49 (95% CI 1.42 to 1.58) and 1.46 (95% 
CI 1.42 to 1.51), respectively. However, for individual 
monitoring PSIs with adequate reliability, the highest 
variation was for M1 (related to monitoring the phys-
ical health of patients receiving an antipsychotic) with 
ICC=0.43 and MOR=4.53 (95% CI 3.89 to 5.36).
Patient and practice characteristics associated 
with potentially hazardous prescribing indicators 
(composite 3)
Table 2 shows the prevalence of patients trig-
gering potentially hazardous prescribing indicators 
(composite 3, P1–P18 excluding P11 and P13) by 
patient and practice- level characteristics, and the 
unadjusted and adjusted ORs (with 95% CIs) derived 
from the two- level logistic regression model. All the 
patient- level characteristics included in the analysis 
were significantly associated with the risk of receiving 
potentially hazardous prescribing in the univariable 
and multivariable models.
In the univariable model, the risk of receiving poten-
tially hazardous prescribing was increasing with age 
and the number of repeat prescriptions. After adjust-
ment, the number of repeat prescriptions continued 
Figure 1 Proportion of (A) patients receiving at least one potentially hazardous prescribing (composite 1) and (B) patients experiencing at least one 
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to have the same relationship; the prevalence of 
hazardous prescribing in patients receiving 0–1 repeat 
prescription was 3.7% compared with 47.4% in those 
with >10 repeat prescriptions (adjusted OR 30.22, 
95% CI 29.44 to 31.02). However, with age, the risk 
of potentially hazardous prescribing increased with 
increasing age until 35–44 years old (adjusted OR 
2.34, 95% CI 2.26 to 2.42) and then began decreasing. 
Women were found to have higher odds of receiving 
potentiality hazardous prescribing than men (18.2% 
vs 12.2% in men, adjusted OR 1.43, 95% CI 1.41 
to 1.45). For the practice- level characteristics, it was 
observed that patients from the most deprived locali-
ties had higher odds of receiving potentially hazardous 
prescribing compared with patients from the least 
deprived localities (adjusted OR 1.10, 95% CI 1.03 
to 1.17). In comparison with England, patients in 
Northern Ireland were at highest risk of receiving 
potentially hazardous prescribing (adjusted OR 1.47, 
95% CI 1.33 to 1.63), followed by Scotland (adjusted 
OR 1.17 95% CI 1.11 to 1.23).
Patient and practice characteristics associated 
with inadequate medication monitoring indicators 
(composite 2)
Table 3 presents the prevalence and ORs for inade-
quate medication monitoring indicators (composite 2, 
M1–M4). Like the potentially hazardous prescribing 
composite, women were found to have a higher risk 
of experiencing inadequate medication monitoring 
than men (adjusted OR 1.12, 95% CI 1.05 to 1.20) 
and patients from the more deprived localities (IMD 
quintiles 3–5) had higher odds of experiencing inad-
equate medication monitoring than patients from the 
Table 2 Prevalence of patients receiving at least one potentially hazardous prescribing (composite 3) by patient and practice- level 
characteristics and multilevel logistic regression unadjusted and adjusted ORs (95% CIs)




  <25 (128 141) 4 (3.9 to 4.1) 1 1
  25–34 (118 374) 9.9 (9.8 to 10.1) 2.62 (2.53 to 2.71) 2.22 (2.14 to 2.30)
  35–44 (115 374) 13.9 (13.7 to 14.1) 3.89 (3.77 to 4.02) 2.34 (2.26 to 2.42)
  45–54 (135 518) 17.7 (17.5 to 17.9) 5.22 (5.06 to 5.38) 2.03 (1.96 to 2.09)
  55–64 (134 562) 19.7 (19.5 to 19.9) 5.89 (5.71 to 6.07) 1.60 (1.55 to 1.65)
  65–74 (120 225) 19.5 (19.3 to 19.7) 5.92 (5.74 to 6.11) 1.16 (1.12 to 1.20)
  >74 (130 459) 22.9 (22.6 to 23.1) 7.41 (7.18 to 7.64) 1.11 (1.08 to 1.15)
Sex
  Male (400 029) 12.2 (12.1 to 12.3) 1 1
  Female (482 624) 18.2 (18.1 to 18.3) 1.6 (1.58 to 1.62) 1.43 (1.41 to 1.45)
Number of drugs on repeat prescription
  0 or 1 (361 502) 3.7 (3.6 to 3.7) 1 1
  2–4 (232 723) 13.2 (13 to 13.3) 3.94 (3.86 to 4.03) 3.99 (3.91 to 4.08)
  5–7 (133 179) 23.4 (23.2 to 23.6) 7.98 (7.81 to 8.15) 9.16 (8.95 to 9.38)
  8–10 (80 072) 32.5 (32.2 to 32.8) 12.55 (12.26 to 12.84) 15.52 (15.12 to 15.93)
  >10 (75 177) 47.4 (47.1 to 47.8) 23.54 (23.01 to 24.08) 30.22 (29.44 to 31.02)
List size
  <6000 (130 159) 16.2 (16 to 16.4) 1 1
  6001–9000 (270 949) 16.4 (16.2 to 16.5) 1.04 (0.97 to 1.12) 1.03 (0.98 to 1.08)
  9001–12 000 (210 388) 15.6 (15.5 to 15.8) 0.99 (0.91 to 1.08) 1.02 (0.96 to 1.08)
  >12 000 (271 157) 14.1 (14 to 14.3) 0.88 (0.81 to 0.96) 1.01 (0.95 to 1.07)
Practice- level index of multiple deprivation quintile
  1 least deprived (151 968) 13.2 (13.1 to 13.4) 1 1
  2 (140 183) 15.3 (15.1 to 15.5) 1.19 (1.08 to 1.31) 1.08 (1.01 to 1.15)
  3 (169 054) 15 (14.8 to 15.2) 1.18 (1.07 to 1.29) 1.03 (0.96 to 1.09)
  4 (195 532) 16.3 (16.1 to 16.4) 1.31 (1.19 to 1.43) 1.08 (1.01 to 1.15)
  5 most deprived (225 916) 16.8 (16.7 to 17) 1.37 (1.25 to 1.51) 1.10 (1.03 to 1.17)
Country
  England (247 545) 13 (12.8 to 13.1) 1 1
  Northern Ireland (35 773) 22 (21.6 to 22.5) 1.91 (1.67 to 2.18) 1.47 (1.33 to 1.63)
  Scotland (328 773) 16.9 (16.8 to 17.1) 1.34 (1.26 to 1.43) 1.17 (1.11 to 1.23)
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least deprived. However, the opposite was observed 
with respect to age and polypharmacy. Patients 
with >10 prescriptions had a lower risk of inadequate 
medication monitoring than patients with 0–1 repeat 
prescription (adjusted OR 0.35, 95% CI 0.29 to 0.41), 
and patients aged >74 had a lower risk than patients 
aged <25 (adjusted OR 0.40, 95% CI 0.31 to 0.51). 
No significant association was observed for the prac-




We found that mental health- related potentially 
hazardous prescribing is common in primary care with 
considerable variation between general practices for 
some indicators even after controlling for differences 
in patient characteristics. The variations were higher 
for indicators related to benzodiazepine and Z- drug 
prescribing and monitoring the physical health of 
patients receiving antipsychotics. In addition, our 
analyses identified a subset of 11 PSIs with adequate 
reliability to distinguish between practices thus making 
them fit for use in benchmarking.47 50
This work could also be regarded as a baseline 
prevalence to evaluate if prescribing safety for people 
with mental illness is improving in primary care.42 
However, it is important to consider that the identi-
fication of PSIs does not necessarily imply error and 
sometimes seemingly hazardous prescribing might be 
the patients’ best option.51 Still, in general, they are 
not considered good practice and should be avoided 
where possible.41 Indeed, our findings related to the 
high rates of inadequate medication monitoring are 
Table 3 Prevalence of patients experiencing at least one inadequate medication monitoring (composite 2) by patient and practice- level 
characteristics and multilevel logistic regression unadjusted and adjusted ORs (95% CIs)




  <25 (2034) 96.3 (95.4 to 97.1) 1 1
  25–34 (4663) 95.9 (95.3 to 96.4) 0.80 (0.60 to 1.05) 0.85 (0.64 to 1.12)
  35–44 (6372) 92.9 (92.3 to 93.5) 0.45 (0.35 to 0.58) 0.52 (0.40 to 0.67)
  45–54 (8558) 90.4 (89.7 to 91) 0.31 (0.25 to 0.40) 0.39 (0.30 to 0.50)
  55–64 (8274) 87.6 (86.9 to 88.3) 0.24 (0.19 to 0.30) 0.31 (0.24 to 0.40)
  65–74 (6051) 85.5 (84.5 to 86.3) 0.19 (0.15 to 0.25) 0.26 (0.20 to 0.34)
  >74 (6927) 89.1 (88.3 to 89.8) 0.28 (0.22 to 0.36) 0.40 (0.31 to 0.51)
Sex
  Male (17 280) 90 (89.6 to 90.5) 1 1
  Female (25 599) 90.3 (89.9 to 90.7) 1.05 (0.98 to 1.13) 1.12 (1.05 to 1.20)
Number of drugs on repeat prescription
  0 or 1 (4208) 95.6 (94.9 to 96.2) 1 1
  2–4 (12 283) 92.3 (91.8 to 92.8) 0.52 (0.44 to 0.62) 0.57 (0.48 to 0.68)
  5–7 (10 016) 89.7 (89.1 to 90.3) 0.37 (0.31 to 0.43) 0.45 (0.38 to 0.53)
  8–10 (7216) 88.8 (88.1 to 89.6) 0.32 (0.27 to 0.38) 0.42 (0.36 to 0.50)
  >10 (9156) 86.5 (85.8 to 87.2) 0.26 (0.22 to 0.30) 0.35 (0.29 to 0.41)
List size
  <6000 (6829) 90.1 (89.4 to 90.8) 1 1
  6001–9000 (14 279) 91.2 (90.8 to 91.6) 1.15 (0.84 to 1.56) 1.12 (0.82 to 1.53)
  9001–12 000 (10 448) 88.3 (87.7 to 88.9) 0.82 (0.58 to 1.17) 0.83 (0.58 to 1.17)
  >12 000 (11 323) 90.7 (90.2 to 91.3) 0.98 (0.68 to 1.41) 1.08 (0.74 to 1.58)
Practice- level index of multiple deprivation quintile
  1 least deprived (5653) 86.9 (86 to 87.7) 1 1
  2 (6799) 90 (89.3 to 90.7) 1.48 (0.98 to 2.24) 1.57 (1.03 to 2.41)
  3 (7884) 91.5 (90.9 to 92.1) 1.88 (1.25 to 2.82) 1.87 (1.23 to 2.84)
  4 (9904) 90.9 (90.4 to 91.5) 1.77 (1.20 to 2.63) 1.85 (1.23 to 2.76)
  5 most deprived (12 639) 90.3 (89.8 to 90.8) 1.56 (1.06 to 2.29) 1.65 (1.11 to 2.46)
Country
  England (9790) 90.2 (89.9 to 90.8) 1 1
  Northern Ireland (2552) 85.9 (84.5 to 87.2) 0.69 (0.37 to 1.28) 0.73 (0.39 to 1.38)
  Scotland (18 489) 89.7 (89.2 to 90.1) 1.11 (0.82 to 1.50) 1.14 (0.84 to 1.55)
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concerning as there is not usually a clinical justifica-
tion for this.42 However, medication monitoring may 
be affected by patient engagement, quality of data 
recording or that the monitoring is performed and 
documented in other settings such as secondary care. 
Nevertheless, current National Institute for Health 
and Care Excellence guidelines indicate that primary 
care should be responsible for antipsychotics (M1) 
and lithium (M3 and M4) monitoring after the first 12 
months of therapy or when the patient’s condition has 
stabilised.52 53
Comparison with other studies
Multiple studies have investigated the safety of 
prescribing in primary care in the UK or Ireland using 
PSIs.41–44 However, comparing these studies to ours is 
not ideal due to the different indicators used. The only 
indicator similarly observed and suitable for compar-
ison is lithium monitoring; Stocks et al observed a 
prevalence of 19.3% for inadequate lithium moni-
toring which is consistent with our subindicator (M3a: 
monitoring lithium plasma levels within the previous 
6 months, 18.61%).42 However, this is lower than our 
overall lithium monitoring indicator (M3: monitoring 
lithium plasma levels within the previous 6 months 
or within the last 3 months if the patient is aged ≥65 
years or has a diagnosis of renal impairment or during 
the first year of treatment, 24.3%).
Most previous studies examined the overall safety 
of prescribing in primary care, whereas we aimed to 
specifically assess mental health- related prescribing. 
Our approach facilitates the examination of the safety 
of prescribing more comprehensively for this vulner-
able patient population, and to provide a clearer esti-
mate of the magnitude of the safety concerns. For 
instance, it has been reported that the risk of receiving 
potentially hazardous prescribing in primary care 
increases with age.41 42 44 In contrast, we found that 
after adjustment, the risk of receiving mental health- 
related potentially hazardous prescribing for patients 
aged 25–64 is higher than older patients. Also, 
although our findings were consistent with previous 
studies in that polypharmacy was strongly associated 
with increasing risk of receiving potentially hazardous 
prescribing, our estimated risk was found to be much 
higher with the odds of receiving at least one mental 
health- related potentially hazardous prescription being 
30 times higher in people with more than 10 repeat 
prescriptions in comparison with people with one 
or no repeat prescription (95% CI 29.44 to 31.02). 
Previous research in the general population in primary 
care reported OR after adjustment ranging from 1.35 
to 10.41–44
The prevalence of the inadequate medication moni-
toring composite indicator was influenced predomi-
nantly by one indicator (M1). Several audits and studies 
from multiple countries have reported high preva-
lence of inadequate metabolic monitoring for people 
prescribed antipsychotic medication.54 55 In addition, a 
systematic review and meta- analysis reported that the 
proportion of patients receiving the monitoring does 
not differ between case record studies and database 
studies.54 Therefore, the quality of documentation 
might not be the main cause for these elevated prev-
alence values. A systematic review identified several 
multidimensional barriers to adequate monitoring for 
patients on antipsychotic medication.56
Considering the variation between practices, it has 
previously been suggested that there are marked vari-
ations in mental health prescribing between general 
practices in the UK.57–60 However, the variation in 
the prevalence of PSIs has only been examined in 
the UK using general (non- mental health specific) 
sets of PSIs.41 42 While the reported ICC (0.03) for 
the prescribing composite is comparable to previous 
publications, and is generally interpreted as low, the 
variation is large in absolute terms (varying from 3.2% 
to 24.1%) and is adequately reliable to detect true 
practice differences,42 47 50 61 which suggest small but 
statistically and clinically significant variation between 
practices.61 However, in the USA, substantial variation 
in prescribing safety between geographical regions 
based on the ‘Coefficient of Variation’ was reported 
using indicators from the Healthcare Effectiveness 
Data and Information Set.62
Strengths and limitations of the study
To our knowledge, this is the first study to specifically 
assess the safety of mental health- related prescribing 
in primary care using a suite of PSIs that were devel-
oped with a panel of mental health experts. We exam-
ined the safety of prescribing in a large population and 
evaluated variation in the prevalence of PSIs between 
general practices across the UK.
This study has several limitations. Due to the nature 
of medical records, we can only examine coded events 
in health records, which could differ from the care 
actually delivered. For example, in a PSI where the 
absence of a test or prescription is the numerator, 
the resulting potential bias may be overestimating the 
prevalence of potentially hazardous care if care was 
delivered but not documented or if it was delivered 
outside of primary care. This is particularly relevant for 
monitoring indicators as some tests could take place in 
secondary care settings or in other specialist mental 
health settings. Conversely, when the presence of a test 
or prescription is the numerator, underestimation is the 
more likely bias. Hence, this would raise the need for 
more effective documentation. Furthermore, included 
practices may not be representative of all the practices 
in their country, particularly when considering the 
smaller number of practices which were included from 
some UK regions. The shift of electronic health record 
providers in general practices from Vision to EMIS 
and TPP SystmOne clinical systems has led to reduc-
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England.63 64 In addition, comparing the findings of 
this research to international data could be compli-
cated due to potential differences in data recording.42 
However, the safety concerns raised are likely to be 
relevant to other countries.35
Implications and suggestions for future research
PSIs represent a valuable and efficient tool to assess 
and monitor the safety of prescribing in populations 
with mental illness. Measuring and identifying a safety 
issue is the first step towards changing practice.65 The 
information obtained by these indicators may enable 
health providers and policymakers to scrutinise crucial 
aspects concerning prescribing, identifying improve-
ment targets, supporting development of improve-
ment efforts to help reduce medication- related harm, 
prioritising efforts for patients with increased risk of 
triggering the indicators and addressing avoidable 
health inequalities.
The implemented PSIs could be used to monitor and 
identify targets for improvement on a national or a 
local level, as with the Medication Safety Dashboard 
and the QOF in the UK.31 66 They could also be used 
to assess the safety of prescribing before and after the 
proposed new and integrated model of primary and 
community mental healthcare in England.67 PSIs could 
also be applied on a patient level to identify individuals 
at risk of medication- related harm and help towards 
achieving the WHO Global Patient Safety Challenge 
of reducing the level of severe, avoidable harm related 
to medicines, as with the successful pharmacist- led 
information technology intervention for medication 
errors (PINCER), the pharmacist- led safety medica-
tion dashboard (SMASH) (based on PINCER PSIs) 
and the Data- Driven Quality Improvement in Primary 
Care programme.21–25 However, further work is still 
needed to explore the practicality of these indicators 
in general practices using either existing interven-
tions that demonstrated effectiveness in improving 
prescribing safety or using new interventions designed 
specifically to support improvement for patients with 
mental illness.
The low reliability for some indicators indicates that 
some practices had inadequate numbers of patients 
‘at risk’ to be used for comparison. However, the 
composite indicators showed adequate reliability 
across all or most practices. However, it is important 
to recognise the disadvantages of composite indicators 
(eg, could be misleading and lack transparency).68 69 
For instance, the monitoring composite (composite 3) 
was dominated by a single indicator. Therefore, for 
the purpose of benchmarking, composite indicators 
along with individual reliable indicators could be used, 
improving our confidence that they correctly define 
practices as having above average or below average 
rates of potentially hazardous prescribing and inade-
quate monitoring.41 In addition, there might be a need 
to regularly review the appropriateness of individual 
indicators within the composites.68 Nevertheless, 
the reliability estimate provided is only relevant to 
compare practices at an aggregated level (meso- level) 
and therefore individual PSIs with low reliability could 
still be used to identify patients at risk of harm for 
improvement interventions at a patient level (micro- 
level) and also to assess the safety nationally or to 
compare it internationally (macro- level).70
Several concerns and opportunities can be drawn 
from these findings, highlighting the need for further 
research into interventions to improve prescribing 
safety for patients with mental illness. Several studies 
have explored means to improve different aspects 
of medication safety issues for patients with mental 
illness, including: specialist mental health clinical 
pharmacy teams in primary care to improve medicine 
optimisation,71 improved and greater collaboration 
between GPs and secondary care,72 increased knowl-
edge and skills training for managing mental illness 
in primary care72 and better communication between 
GPs and psychiatrists to help improve metabolic moni-
toring for patients on antipsychotics.73 We envisage 
that our PSIs may be used to guide these improvement 
efforts, and could play an important role in developing 
new services for reviewing mental health medications 
delivered by the primary care networks.10
Future research should also focus on the predictive 
validity of these indicators. The PSIs in our study may 
have adequate face and content validity as they were 
developed using the Delphi consensus approach after 
reviewing the available evidence supporting each indi-
cator.35 However, their predictive validity in terms 
of patient outcomes remains uncertain. Therefore, 
future work needs to investigate how well these PSIs 
can predict harm and hospital admission. In addition, 
with unexplained variations in the prevalence of PSIs 
observed between practices, there is a need to eluci-
date the sources of these variations which may be due 
to differences in the prevalence of patient comorbidi-
ties, differences in data recording or in local treatment 
policies and guidelines.
CONCLUSION
This is the first study to specifically assess the safety 
of mental health- related prescribing in primary care 
using a tailored suite of PSIs. The findings suggest 
that potentially hazardous prescribing and inade-
quate medication monitoring are common in those 
with mental illness in primary care with high varia-
tion between practices for some indicators. The infor-
mation obtained by the indicators may enable health 
providers to identify improvement targets and support 
development of improvement efforts to help reduce 
medication- related harm for people with mental 
illness. This study has also identified a subset of indi-
cators and composite indicators with good reliability 
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